Hanzhou Yian Jishi Biopharmaceutical

Yian Jishi is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the discovery and development of innovative antibody therapeutics for oncology. The company focuses on next-generation immunotherapy, particularly bispecific antibodies and monoclonal antibodies targeting immune checkpoints and tumor-associated antigens. Their lead programs include therapies targeting the PD-1/CTLA-4 and Claudin 18.2 pathways, aimed at addressing unmet needs in solid tumors such as gastric and lung cancers. Yian Jishi leverages a proprietary technology platform to optimize the efficacy and safety profiles of its biologic candidates.